Emerging Biomarkers and Therapeutic Targets in Cancer Immunotherapy
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Immunology and Immunotherapy".
Deadline for manuscript submissions: closed (30 April 2024) | Viewed by 1252
Special Issue Editor
Interests: carotid plaques; atherosclerotic plaque; checkpoint inhibitors; exosomes; cancer immunotherapy
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Despite the successes in cancer management, some immunotherapies can dysregulate the immune system, leading to immune-mediated adverse events. Extracellular vesicles (Evs), including exosomes, are emerging as key players in tumor immunology. Importantly, tumor-derived EVs (TDEs) contain a unique molecular signature that is reflective of the tumor's underlying genetic complexity. They offer a glimpse into the immune tumor microenvironment (TME) and have the potential to be a novel, minimally invasive biomarker for cancer immunotherapy. Immune checkpoint inhibitors (ICI), such as anti-programmed death-1(PD-1), its ligand (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)- antibodies, have revolutionized the treatment of a wide variety of tumors. Despite the success of many cancer immunotherapies, such as CAR-T therapy, there is still a need for noninvasive or minimally invasive biomarkers both for diagnosis and treatment monitoring. The targeted analysis of markers in biospecimens such as plasma could serve this purpose by potentially obviating the need for a tissue sample. Therefore the purpose of this Special Issue is analyze the current challenges in the selection of biomarkers and therapeutic targets in cancer immunotherapy to modulate the antitumor immune response.
Dr. Wioletta Olejarz
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- immonotherapy
- CAR-T therapy
- biomarkers
- immune checkpoint inhibitors
- extracellular vesicles
- exosomes
- drug resistance
- drug discovery
- therapeutic regimens
